Combined integrin αvβ3 and lactoferrin receptor targeted docetaxel liposomes enhance the brain targeting effect and anti-glioma effect

Qi, Na; Zhang, Shangqian; Zhou, Xin; Duan, Wenjuan; Gao, Duan; Jiao, Feng; Li, Aimin

doi:10.1186/s12951-021-01180-0

Cited by 34 publications

(29 citation statements)

References 42 publications

(72 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, lactoferrin (Lf), a multifunctional glycoprotein, is only expressed in brain capillaries. Qi et al ( 174 ) indicated that a targeted delivery system modified by Lf is able to markedly improve the ability of docetaxel liposomes to cross the BBB and enhance brain targeting effects, demonstrating its potential as a promising chemotherapeutic drug delivery system for glioblastoma. Angiopep-2 (Ang) is able to specifically bind to receptor-related protein 1 (LRP-1), which is highly expressed on the glioma cell membrane.…”

Section: Future Perspectivesmentioning

confidence: 99%

NcRNAs: Multi‑angle participation in the regulation of glioma chemotherapy resistance (Review)

et al. 2022

View full text Add to dashboard Cite

As the most common primary tumour of the central nervous system, gliomas have a high recurrence rate after surgical resection and are resistant to chemotherapy, particularly high-grade gliomas dominated by glioblastoma multiforme (GBM). The prognosis of GBM remains poor despite improvements in treatment modalities, posing a serious threat to human health. At present, although drugs such as temozolomide, cisplatin and bevacizumab, are effective in improving the overall survival of patients with GBM, most patients eventually develop drug resistance, leading to poor clinical prognosis. The development of multidrug resistance has therefore become a major obstacle to improving the effectiveness of chemotherapy for GBM. The ability to fully understand the underlying mechanisms of chemotherapy resistance and to develop novel therapeutic targets to overcome resistance is critical to improving the prognosis of patients with GBM. Of note, growing evidence indicates that a large number of abnormally expressed noncoding RNAs (ncRNAs) have a central role in glioma chemoresistance and may target various mechanisms to modulate chemosensitivity. In the present review, the roles and molecular mechanisms of ncRNAs in glioma drug resistance were systematically summarized, the potential of ncRNAs as drug resistance markers and novel therapeutic targets of glioma were discussed and prospects for glioma treatment were outlined. ncRNAs are a research direction for tumor drug resistance mechanisms and targeted therapies, which not only provides novel perspectives for reversing glioma drug resistance but may also promote the development of precision medicine for clinical diagnosis and treatment.

show abstract

Section: Future Perspectivesmentioning

confidence: 99%

NcRNAs: Multi‑angle participation in the regulation of glioma chemotherapy resistance (Review)

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Lactoferrin (Lf) is a natural protein, 80 kDa glycoprotein, and belongs to the transferrin family [ 153 , 154 ]. Lactoferrin-based liposomes have been used as ligands of the lactoferrin receptor (LfR) to reach some cancers, such as liver and brain tumors [ 155 , 156 ], and as ligands of other overexpressed receptors [ 157 , 158 ]. Several recent studies demonstrated that Lf is a potential liposome ligand for targeting numerous receptors overexpressed in tumors, improving anticancer activity, increasing cellular uptake and simultaneously lowering side effects.…”

Section: Nanocarriers For Targeted Cancer Therapymentioning

confidence: 99%

Functionalized Liposome and Albumin-Based Systems as Carriers for Poorly Water-Soluble Anticancer Drugs: An Updated Review

2022

View full text Add to dashboard Cite

Cancer is one of the leading causes of death worldwide. In the available treatments, chemotherapy is one of the most used, but has several associated problems, namely the high toxicity to normal cells and the resistance acquired by cancer cells to the therapeutic agents. The scientific community has been battling against this disease, developing new strategies and new potential chemotherapeutic agents. However, new drugs often exhibit poor solubility in water, which led researchers to develop functionalized nanosystems to carry and, specifically deliver, the drugs to cancer cells, targeting overexpressed receptors, proteins, and organelles. Thus, this review is focused on the recent developments of functionalized nanosystems used to carry poorly water-soluble drugs, with special emphasis on liposomes and albumin-based nanosystems, two major classes of organic nanocarriers with formulations already approved by the U.S. Food and Drug Administration (FDA) for cancer therapeutics.

show abstract

“…The modification of two different ligands may lead to better and controllable lesion site selectivity (Gao, 2016; Ruan et al, 2021). Several peptides or proteins were utilized in this field, including ApoA‐I, angiopep‐2, T7, and lactoferrin for BBB overcoming and NL4, CD133 antibody, RGD, NGR, and D A7R for targeting lesion site (Fu et al, 2019; Kim, Shin, & Kim, 2018; Qi et al, 2021; Zhang, Gu, et al, 2017; Zhang, Zhai, et al, 2017). Notably, although the dual targeting delivery system enables precise multiple targeting capabilities, the in vivo process and clinical translation of the delivery system are limited due to the complex modification process.…”

Section: Bbb Alteration In Brain Diseases and Targeting Delivery Stra...mentioning

confidence: 99%

Brain‐targeting drug delivery systems

Liu

Jiang

2022

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Brain diseases, including neurodegenerative diseases, acute ischemic stroke and brain tumors, have become a major health problem and a huge burden on society with high morbidity and mortality. However, most of the current therapeutic drugs can only relieve the symptoms of brain diseases, and it is difficult to achieve satisfactory therapeutic effects fundamentally. Extensive studies have shown that the therapeutic effects of brain diseases are mainly affected by two factors: the conservation of the blood–brain barrier (BBB) and the complexity of the brain micro‐environment. Brain‐targeting drug delivery systems provide new possibilities for overcoming these barriers with versatility. In this review, it provides an overview of BBB alteration and discusses targeting delivery strategies for brain diseases therapy. Furthermore, delivery systems which are designed to modulate the brain micro‐environment with synergistic effects were also highlighted. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies

show abstract

Combined integrin αvβ3 and lactoferrin receptor targeted docetaxel liposomes enhance the brain targeting effect and anti-glioma effect

Cited by 34 publications

References 42 publications

NcRNAs: Multi‑angle participation in the regulation of glioma chemotherapy resistance (Review)

NcRNAs: Multi‑angle participation in the regulation of glioma chemotherapy resistance (Review)

Functionalized Liposome and Albumin-Based Systems as Carriers for Poorly Water-Soluble Anticancer Drugs: An Updated Review

Brain‐targeting drug delivery systems

Contact Info

Product

Resources

About